Literature DB >> 12427775

Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium.

K K Basu1, B Pick, R Bale, K P West, J S de Caestecker.   

Abstract

INTRODUCTION: Barrett's epithelium (BE) has malignant potential. Neither acid suppression nor antireflux surgery produce consistent or complete regression of the metaplastic epithelium. Endoscopic thermoablation with argon plasma coagulation (APC) offers a different approach but factors influencing its outcome have not been systematically examined. AIM: To assess the efficacy of APC and factors influencing initial and one year outcome.
METHODS: Fifty patients, mean age 61.4 years, mean BE length 5.9 cm (range 3-19), underwent APC therapy at four weekly intervals while receiving proton pump inhibitor (PPI) therapy. BE margins were marked by India ink tattooing and extent was documented by grid drawings, photography, and 2 cm interval quadrantic jumbo biopsies. Twenty four hour ambulatory oesophageal pH studies were done while on PPIs before and after APC therapy, and Bilitec bilirubin monitoring after APC completion.
RESULTS: A total of 68% of patients achieved >90% BE ablation after a median of four APC sessions. Persistent BE (>10% original BE area) was associated with longer initial BE length despite more APC sessions. Persistent acid and bile reflux on PPIs, although commoner in this group, were not significantly different from those successfully ablated. Fifteen of 34 patients (44%) with successful macroscopic clearance had buried glands, present in 8.3% of a total of 338 biopsies. At the one year follow up, only 32% of those with initial successful ablation showed no recurrence. BE recurred or increased in most with mean segment length increases of 1.1 cm and 1.6 cm, respectively, in patients with previous full ablation and those with persistent BE. The presence of buried glands did not predict BE recurrence. Patients who reduced their PPI dose had significantly greater BE recurrence.
CONCLUSIONS: APC is most effective for shorter segment BE ablation but "buried" glands do occur. Recurrence of BE is common at one year, especially in those with initial persistent and/or long segment BE and those who reduce their PPI dose.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427775      PMCID: PMC1773469          DOI: 10.1136/gut.51.6.776

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  31 in total

1.  Argon plasma coagulation (APC) in gastroenterology: experimental and clinical experiences.

Authors:  W Johanns; W Luis; J Janssen; S Kahl; L Greiner
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-06       Impact factor: 2.566

2.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

Authors:  D J Drewitz; R E Sampliner; H S Garewal
Journal:  Am J Gastroenterol       Date:  1997-02       Impact factor: 10.864

3.  Changing patterns and surgical results in adenocarcinoma of the oesophagus.

Authors:  P Thomas; C Doddoli; P Lienne; N Morati; X Thirion; L Garbe; R Giudicelli; P Fuentes
Journal:  Br J Surg       Date:  1997-01       Impact factor: 6.939

Review 4.  Endoscopic ablation of Barrett's epithelium.

Authors:  J S de Caestecker
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-07       Impact factor: 2.566

5.  Omeprazole works best when used properly.

Authors:  D O Castell
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-05       Impact factor: 2.566

6.  Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.

Authors:  P Sharma; R E Sampliner; E Camargo
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

7.  Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized.

Authors:  W K Kauer; J H Peters; T R DeMeester; A P Ireland; C G Bremner; J A Hagen
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

Review 8.  The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett.

Authors:  S J Spechler; R K Goyal
Journal:  Gastroenterology       Date:  1996-02       Impact factor: 22.682

Review 9.  Early detection of neoplasia of the esophagus and gastroesophageal junction.

Authors:  R H Riddell
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

10.  Regression and progression of Barrett's oesophagus after antireflux surgery.

Authors:  P M Sagar; R Ackroyd; K B Hosie; J E Patterson; C J Stoddard; A N Kingsnorth
Journal:  Br J Surg       Date:  1995-06       Impact factor: 6.939

View more
  29 in total

1.  Argon plasma coagulation therapy for ablation of Barrett's oesophagus.

Authors:  J Deviere
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

2.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

3.  Endoscopic therapy of Barrett's: what more do we need to know?

Authors:  J-L Van Laethem; J Devière
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

4.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

Review 5.  Endoscopic therapy for Barrett's oesophagus.

Authors:  H Barr; N Stone; B Rembacken
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 6.  Potent gastric acid inhibition in the management of Barrett's oesophagus.

Authors:  Angel Lanas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

8.  Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus.

Authors:  Junichi Akiyama; Samuel N Marcus; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2012-08-10       Impact factor: 3.199

Review 9.  Endoscopic therapy for confirmed low-grade dysplasia in Barrett's esophagus.

Authors:  Silvia Pecere; Guido Costamagna
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-29

10.  Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation.

Authors:  Ahmed Madisch; Stephan Miehlke; Ekkehard Bayerdorffer; Birgit Wiedemann; David Antos; Anke Sievert; Michael Vieth; Manfred Stolte; Heinrich Schulz
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.